The MYCN oncoprotein is implicated in various human cancers, including high-risk neuroblastoma, making tumors less responsive to immunotherapy. Boston University researchers found that MYCN increases levels of the signaling molecule CKLF in neuroblastoma cells, suppressing anti-tumor immune responses and promoting aggressiveness. Studying experimental models and patient samples, they aim to develop effective immunotherapeutic strategies to improve treatments for high-risk neuroblastoma. Understanding how tumor cells use CKLF to affect immune responses could lead to less toxic treatments. The research, published in Science Advances, is crucial for uncovering therapeutic approaches to enhance anti-tumor immune responses in MYCN-driven childhood cancers.
Source link
BU study reveals key to combating high-risk neuroblastoma
